Innovative retatrutide, a dual -action medication targeting equally GLP-1 and GIP receptors, is creating considerable excitement within the healthcare community. Preliminary clinical research have shown substantial losses in overall size and gains in health markers for patients with excess weight . Scientists believe this ground-breaking approach